Prevalence of Folate Receptor Alpha in Adult Women with Ovarian Cancer Across InterCon Countries

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective observational study that analyzes archived ovarian cancer tissue to measure folate receptor alpha (FRa) expression by immunohistochemistry. Data will be collected from about 1,000 participants, with testing performed on archival samples within a one-year timeframe. No treatments or drugs are given to participants; researchers review medical charts and analyze FFPE tumor specimens to assess FRa concordance. Eligible samples must be high-grade serous ovarian cancer with sufficient viable tumor cells and be no more than five years old. The study aims to understand FRa prevalence to inform future FRa-targeted approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Surgical or biopsy samples (Formalin Fixed Paraffin Embedded \[FFPE\]) with tumoral High Grade Serous Ovarian Cancer (HGSOC) material allowing the sectioning of serial slides for all the analyses.
* Archival specimens should not be older than 5 years in order to control quality of the samples.
* Specimens containing a minimum of 100 viable tumor cells.

Exclusion Criteria:

* Surgical or biopsy samples (FFPE) with insufficient quantity or quality (sampled more than 5 years ago and/or with less 100 viable tumor cells per section).
* Tissue obtained following treatment with Mirvetuximab soravtansine or any other FRa targeted therapy.
* Tissue obtained through fine needle aspirations or liquid specimens, or ascites

Where it's running

• Biomakers /ID# 280318
  Buenos Aires, Buenos Aires, Argentina Recruiting
• Hospital Italiano de Buenos Aires /ID# 280315
  Buenos Aires, Buenos Aires, Argentina Recruiting
• Instituto Alexander Fleming /ID# 281479
  Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina Recruiting
• A.C. Camargo Cancer Center - Rua Professor Antonio Prudente /ID# 280407
  São Paulo, São Paulo, Brazil Recruiting
• Brazil - Generic Institution /ID# 287000
  São Paulo, Brazil Recruiting
• Toronto General Hospital-University Health Network /ID# 282521
  Toronto, Ontario, Canada Recruiting

Study contacts

• Study coordinator: Rebekah Taylor
• Email: rebekah.taylor@abbvie.com
• Phone: (847) 937-8000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• CR-002 study in adults with advanced solid tumors

  This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors

  Recruiting at 3 sites Phase 1/2 Crescent Biopharma, Inc. · Austin, Texas and 2 other locations · NCT07909031

• VT-101 in Advanced Ovarian Cancer: early safety study in adults

  This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.

  Recruiting Phase 1 University of Iowa · Iowa City, Iowa · NCT07905677

• Methylation markers in self-samples to help detect gynecological cancers

  This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.

  Recruiting Universiteit Antwerpen · Edegem, Antwerp · NCT07902375

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• EHR-based approach to boost HBOC genetic testing in at-risk women

  A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.

  Recruiting Columbia University · New York, New York · NCT07876349

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.